U.S. Stock News

In February 2026, Rapid7, Inc. reported its fourth-quarter 2025 results, with revenue of US$217.39 million and net income of US$3.13 million, alongside full-year 2025 revenue of US$859.79 million and net income of US$23.38 million. The company also issued 2026 guidance that points to a GAAP loss in the first quarter but a return to GAAP profitability for the full year, giving investors fresh insight into its near-term growth and margin path. Now we’ll examine how Rapid7’s modest quarterly...

Brookfield Wealth Solutions (BNT) has wrapped up FY 2025 with Q4 revenue of about US$3.1b and basic EPS of roughly US$0.03, capping a year in which trailing 12 month revenue came in at US$11.6b and EPS at US$2.49. The company has seen quarterly revenue move between US$2.6b and US$3.1b across FY 2025, while basic EPS swung from a loss of US$0.90 in Q1 2025 to US$1.89 in Q3 2025 and US$0.03 in Q4 2025. This puts the focus on how consistently those earnings can convert into lasting...

Regulators are increasing scrutiny of Zoetis' monoclonal antibody pain therapies, including Librela, leading to updated FDA safety warnings. At the same time, Zoetis has received approvals for new osteoarthritis pain drugs, Lenivia and Portela, expanding its pet pain management portfolio. These parallel developments highlight a shift in the company’s risk profile and opportunity set in companion animal health. For investors tracking Zoetis, ticker NYSE:ZTS, the stock sits at $126.65 with a...

Tyler Technologies (NYSE:TYL) announced the acquisition of For The Record, a company focused on digital court recording solutions. The company is rolling out early access to embedded AI features across its product set for interested clients. Tyler also introduced a new share repurchase program of up to US$1b. Tyler Technologies focuses on software and services for public sector clients, including courts, justice systems and local governments. By adding For The Record, the company is...

If you are wondering whether Halozyme Therapeutics at around US$79.44 is still attractively priced or starting to look expensive, this article takes a closer look at what the current market price might be implying. Over shorter horizons the stock has been mixed, with a 2.2% decline over the last 7 days, an 8.9% return over 30 days, a 13.0% return year to date, and a 36.3% return over 1 year. The 3 year and 5 year returns sit at 58.8% and 59.9% respectively. Recent interest in Halozyme...

Agnico Eagle Mines (NYSE:AEM) FY 2025 earnings snapshot Agnico Eagle Mines (NYSE:AEM) closed out FY 2025 with Q4 revenue of US$3.6 billion and basic EPS of US$3.04, while trailing twelve month revenue reached US$11.9 billion and EPS came in at US$8.89, alongside a 135.4% rise in earnings over the last year. Over recent periods, the company has seen revenue move from US$8.3 billion and EPS of US$3.79 on a trailing basis at the end of 2024 to US$11.9 billion and EPS of US$8.89 by Q4 2025, with...

If you are wondering whether Exact Sciences is still worth your attention at current prices, the key question is how its market value compares with what the business may be worth on paper. The stock last closed at US$103.24, with returns of 0.1% over 7 days, 1.0% over 30 days, 1.5% year to date, 109.4% over 1 year, 62.6% over 3 years, and a 30.2% decline over 5 years. Recent news around Exact Sciences has focused on its position in cancer diagnostics and how its core products fit into...

If you are wondering whether Aon is pricing in too much optimism or not enough, this article will walk through what its current share price might be implying about value. The stock last closed at US$321.70, with returns of 5.9% decline over 7 days, 7.0% decline over 30 days, 6.6% decline year to date, 16.2% decline over 1 year, 6.3% gain over 3 years and 46.5% gain over 5 years. This gives you a mix of shorter term weakness and longer term strength to think about. Recent coverage has focused...

Karyopharm Therapeutics FY 2025 earnings snapshot Karyopharm Therapeutics (KPTI) closed FY 2025 with Q4 revenue of US$34.1 million and a basic EPS loss of US$5.68, alongside a net loss of US$102.2 million. On a trailing twelve month basis, EPS stood at a loss of US$17.93 on revenue of US$146.1 million and a net loss of US$196.0 million. The company has reported quarterly revenue ranging from US$30.0 million to US$44.0 million over the past year, with basic EPS losses between US$2.77 and...

Air Lease (NYSE:AL) is working through a pending merger with Sumisho Air Lease Corporation that could reshape how the business is organized and funded. The potential transaction raises questions around future operations, financing options, and how the combined entity might serve airline customers. Investors are watching closely as the company evaluates this merger alongside its current trading level near $64.73 per share. With Air Lease trading around $64.73, investors are weighing this...

Evolv Technologies Holdings (EVLV) has drawn fresh attention after securing new deployments of its AI-based weapons detection systems at major US sports venues, alongside appointing Axon executive Henrik Kühl to its board and audit committee. See our latest analysis for Evolv Technologies Holdings. The recent sports venue wins and board changes come after a mixed stretch for the stock, with a 7 day share price return of 3.46% but a 30 day share price decline of 13.68%. At the same time, the 1...

In early February 2026, ATI Inc. reported fourth-quarter 2025 sales of US$1,177.1 million with net income of US$96.6 million, while full-year sales rose to US$4,587.4 million and net income to US$404.3 million, alongside the completion of a US$580.16 million buyback covering 8,343,988 shares since September 2024. Management highlighted that robust aerospace and defense demand, a richer mix of proprietary alloys, and expanded long-term agreements supported stronger-than-expected non-GAAP...

The Buckle, Inc. previously reported that net sales for the 4-week fiscal month ended January 31, 2026 rose 3.7% to US$61.8 million, with comparable store gains extending across the fourth quarter and full fiscal year. With full-year net sales increasing to US$1.30 billion and comparable store sales higher across all periods, Buckle’s latest update highlights consistent demand across its store base. Next, we’ll examine how this broad-based comparable sales growth may influence Buckle’s...

Redwood Trust (RWT) closed out FY 2025 with Q4 total revenue of US$87.3 million and basic EPS of US$0.14, marking a clear rebound from the loss making quarters seen earlier in the year. Over the past few periods, the company has seen revenue move from US$30.9 million in Q4 2024 to US$73.8 million in Q1 2025, fall to US$54.4 million in Q3, then climb to US$87.3 million in Q4. Basic EPS shifted from US$0.09 in Q1 2025 to a loss of US$0.76 in Q2 and back into positive territory in Q4. For...

Morningstar (MORN) has wrapped up FY 2025 with fourth quarter total revenue of US$641.1 million and basic EPS of US$2.84, capping a year where trailing twelve month revenue reached US$2.4 billion and EPS came in at US$8.93. Over the past few quarters, the company has seen quarterly revenue move from US$581.9 million in Q1 2025 to US$641.1 million in Q4, while basic EPS stepped from US$1.83 to US$2.84 over the same stretch, supported by earnings growth of 15.2% over the last year and net...

Bright Horizons Family Solutions (BFAM) has put fresh numbers on the table for FY 2025, with Q4 revenue of US$733.7 million and basic EPS of US$0.39. Trailing 12 month revenue sits at about US$2.9 billion against EPS of US$3.39. Over recent quarters, revenue has ranged from US$665.5 million to US$802.8 million as basic EPS moved between US$0.66 and US$1.38. Trailing 12 month net income rose from US$140.2 million to US$193.1 million, giving investors a clearer read on how margins are shaping...

Evolution Petroleum (EPM) just posted Q2 2026 results with revenue of US$20.7 million, basic EPS of US$0.03 and net income of US$1.0 million, set against trailing 12 month revenue of US$85.6 million and basic EPS of US$0.08. Over the last year, revenue has been running in the US$85 million range while net income on a trailing basis has moved to US$2.7 million, giving investors a clearer picture of how recent quarters are feeding into the longer term earnings line. With net margin at 3.2% over...

Four Corners Property Trust (FCPT) has wrapped up FY 2025 with fourth quarter total revenue of US$75.7 million, basic EPS of US$0.28 and funds from operations of US$45.7 million, giving investors a fresh look at the REIT's cash generation. Over the past six quarters, the company has seen total revenue move from US$66.8 million in Q3 2024 to US$75.7 million in Q4 2025. Trailing twelve month revenue sits at US$294.1 million and EPS at US$1.09, framing the latest results for income-focused...

Williams Companies (NYSE:WMB) has completed a series of major pipeline and offshore projects and formed a new partnership with Woodside Energy. The company has launched ten new initiatives across pipeline transmission, gathering, storage, and power-related projects. Williams has sold its Haynesville E&P business and outlined substantial new growth capital commitments. The company has also announced a 5% dividend increase alongside its latest expansion plans. For investors watching NYSE:WMB,...

Alexander's (ALX) is back in focus after its latest earnings release, where fourth quarter results came in below analyst expectations and both revenue and net income declined compared with the prior year period. See our latest analysis for Alexander's. The recent earnings miss and weaker profitability seem to have weighed on sentiment, with a 7 day share price return of negative 8.31%. However, the 90 day share price return of 8.01% and 1 year total shareholder return of 24.14% suggest longer...

MVB Financial (MVBF) has wrapped up FY 2025 with fourth quarter revenue of US$36.9 million and basic EPS of US$0.33, set against trailing twelve month revenue of US$158.9 million and EPS of US$2.11 that frame the full year earnings picture. Over recent periods, the company has seen quarterly revenue move between US$31.7 million and US$56.8 million, while basic EPS has ranged from US$0.16 to US$1.36, giving investors a wide band of outcomes to weigh as they assess the latest print. With a...

Bio-Rad Laboratories (BIO) has put up a mixed set of numbers for Q3 FY 2025, with revenue of US$653 million and a basic EPS loss of US$12.70, against a backdrop of prior quarters that ranged from EPS of US$23.37 on US$649.7 million of revenue in Q3 FY 2024 to a loss of US$25.57 on US$667.48 million of revenue in Q4 FY 2024. Over the past few quarters, revenue has generally sat in the US$585 million to US$667 million band, while EPS has swung sharply between gains and losses. Investors will...

Centessa Pharmaceuticals (CNTA) has drawn fresh attention after outlining 2026 plans for its orexin pipeline, including moving lead asset ORX750 toward registrational studies and advancing ORX142 into clinical trials, while also preparing for a pre-commercial shift. See our latest analysis for Centessa Pharmaceuticals. The recent orexin updates come after a mixed price pattern, with a 1 month share price return of 11.86% and a 3 month share price return decline of 10.5%. However, the 3 year...

In the past week, Harley-Davidson reported fourth-quarter 2025 results showing a net loss of US$279.3 million and a basic loss per share of US$2.44, alongside weaker full-year profitability and a completed US$500.72 million share buyback that retired 16,576,158 shares. At the same time, management framed 2026 as a transition year focused on resetting dealer inventory and profitability, while S&P Global Ratings warned its investment-grade credit rating could be cut to junk pending a new...